In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

Member Benefit

This content is only available year-round to ESC Professional Members, Fellows of the ESC, and Young Combined Members

Controversies in Heart Failure: SGLT2 Inhibitors Should Be Given to All Patients
Session

Event : ESC Congress 2020

Topic : Chronic Heart Failure

  • Session type : Debate Session
  • Date : 31 August 2020
  • Time : 09:25 - 10:05

Member Benefit

This content is only available year-round to ESC Professional Members, Fellows of the ESC, and Young Combined Members

3 presentations in this session

SGLT2 inhibitors should be given to all patients with heart failure - PRO.

Event : ESC Congress 2020

  • Session : Controversies in Heart Failure: SGLT2 Inhibitors Should Be Given to All Patients
  • Speaker : JJV McMurray (Glasgow,GB)

SGLT2 inhibitors should be given to all patients with heart failure - CON.

Event : ESC Congress 2020

  • Session : Controversies in Heart Failure: SGLT2 Inhibitors Should Be Given to All Patients
  • Speaker : R De Boer (Groningen,NL)

SGLT2 inhibitors should be given to all patients with heart failure - Discussion.

Event : ESC Congress 2020

  • Session : Controversies in Heart Failure: SGLT2 Inhibitors Should Be Given to All Patients

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are